MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:44Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Insulins]]
			[[Category:Ultra-long-acting insulins]]
			[[Category:Basal insulins]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #152

2026-05-23T04:19:17Z

parser-claude batch MedTemplate pre-fill, Top 300 #152

New page

{{MedTemplate
| generic = Insulin degludec
| brand = Tresiba
| structure =
| classes = [[:Category:Insulins|Insulin]], [[:Category:Ultra-long-acting_insulins|Ultra-long-acting insulin analog]], [[:Category:Basal_insulins|Basal insulin]]
| uses = <vote slug="type1-diabetes-use">Type 1 diabetes mellitus</vote>, <vote slug="type2-diabetes-basal-use">Type 2 diabetes basal coverage</vote>
| starting_dose = ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose
| preparations = 100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience)
| fda_max = Titrated to glucose; no fixed ceiling
| pill_id =
| routes = Subcutaneous (never IV; not for use in insulin pumps)
| onset = ~1 hour
| duration = >42 hours per dose (effectively flat once at steady state)
| halflife = ~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)<ref name="tresiba-label">FDA Prescribing Information, Tresiba (insulin degludec), Novo Nordisk, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/203314s022lbl.pdf</ref>
| bioavailability = ~100% from subcutaneous depot
| pregnancy = Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="degludec-mech-claim">Insulin degludec self-assembles after subcutaneous injection into long multi-hexamer chains that slowly dissociate into monomers, providing a flat ultra-long-duration insulin profile (>42 hours) that supports forgiving dose-timing windows and lower nocturnal hypoglycemia rates than glargine in DEVOTE and SWITCH trials.</vote> Binds the same insulin receptor as endogenous insulin with comparable mitogenic-to-metabolic ratio<ref name="tresiba-label" />.
}}

== References ==
<references />

Insulin Degludec - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #152